Buy and Bill is one of the most common ways clinics deliver Spravato treatment.
It also carries the highest financial risk when set up incorrectly.
Many practices start with the right intent but run into issues within the first few months. Margins shrink, inventory becomes hard to track, and reimbursements do not match expectations.
This usually happens because the setup was incomplete.
At Finnastra, we work with clinics that either want to launch Buy and Bill or fix what is already in place. Our Spravato Billing Services are designed to simplify this model so clinics protect margins from day one.
In a Buy and Bill model, your clinic:
This gives you control over treatment delivery and scheduling.
It also means you carry upfront drug costs.
For most clinics, each treatment dose ranges between $500 to $900 depending on dosage and pricing agreements. Reimbursement varies by payer but often falls between $1300 to $1600 when billed correctly.
The margin exists but only if the system is built properly.
The risk is not in the model itself. The risk is in how it is managed.
We see the same issues repeatedly:
Many clinics believe they are profitable until they review actual numbers.
In reality, small inefficiencies across purchasing, billing, and collections create consistent revenue leakage.
Step 1: Choose the Right Distributor Strategy
Do not settle for the first option.
There are multiple distributors offering Spravato. Pricing varies based on volume, negotiation, and relationship.
We support Buy and Bill by helping clinics compare distributor pricing and secure better rates. Even a small difference per dose impacts long term margins.
Once you choose a distributor, build a clear inventory process.
You need to track:
Inventory should always match what is billed.
If these numbers do not align, you risk audit exposure and financial loss.
This is one of the most important steps.
Your Prior Authorization for Spravato must match how you plan to bill.
That includes:
If authorization and billing are misaligned, claims get denied or underpaid.
As a leading Spravato Billing Services Company, Finnastra ensures this alignment is handled before treatment begins.
Accuracy in coding determines reimbursement.
Clinics must correctly bill:
Errors here are common. Even experienced teams struggle when payer rules vary.
This is where specialized expertise matters.
Submission is only half the process.
You must actively track:
Industry benchmarks show that 10 to 20 percent of healthcare claims face initial denial. Without active follow-up, a large portion of that revenue is never recovered.
Do not assume profitability.
Track:
This gives you a clear picture of performance.
High-performing clinics review this monthly, not quarterly.
Clinics that succeed with Buy and Bill focus on control and visibility.
They:
When you work with a dedicated Spravato Billing Company like Finnastra, this level of control becomes part of your daily operations.
If these answers are unclear, your margins are at risk.
We support Buy and Bill as a full system, not a single step.
Our Spravato Billing Services are designed to simplify complex processes so clinics can focus on patient care while maintaining financial control.
Most billing companies focus on claim submission.
That is only one part of the equation.
As a Top Spravato Billing Company in U.S, Finnastra works across purchasing, authorization, billing, and collections.
We support Buy and Bill in a way that protects your margins and stabilizes your revenue.
Buy and Bill works well when the system is built correctly.
When it is not, clinics face hidden losses that compound over time.
The difference comes down to setup, alignment, and ongoing monitoring.
If you are planning to start or improve your Spravato program, Finnastra can help you build a structure that supports both care delivery and financial performance.
